Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines

Bibliography

• Tepper J, Stillman J. What is the best drug-delivery approach for the acute treatment of migraine? Expert Rev. Neurother 2012;12(3):253-5
   Google Scholar
• Matchar DB, Young WB. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Copyright © by the American Academy of Neurology: Licensed to the members of the US Headache Consortium.
   Google Scholar
• Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59(7):1084-8
   PubMedGoogle Scholar
• Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9(1):5-12
   PubMed Web of Science ®Google Scholar
• Hamel E.. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007;27:1295-300
   Web of Science ®Google Scholar
• Glen RC, Martin GR, Hill AP, Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compound with potential antimigraine properties. J Med Chem 1995;38(18):3566-80
   PubMedGoogle Scholar
• Martin GR, Robertson AD, MacLennan SJ, Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (Zolmitriptan). Br J Pharmacol 1997;121(2):157-64
   PubMedGoogle Scholar
• Shepheard SL, Williamson DJ, Cook DA, Preclinical comparative studies on the sympatholytic effects of 5-HT1D receptor agonists in vivo. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment. Trial methodology and new trials. Lippincot-Raven; PA, USA: 1997. p. 293-302
   Google Scholar
• De Hoon JNJM, Willgers JM, Troost J, Vascular effects of 5HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000;68:418-26
   PubMed Web of Science ®Google Scholar
• Humphrey PPA, Feniuk W, Perren MJ, The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989;9(Suppl 9):23-33
   PubMedGoogle Scholar
• Dixon R, Gillotin C, Gibbens M, The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan. (311C90) in healthy volunteers. Br J Clin Pharmacol 1997;43(3):273-81
   PubMedGoogle Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
   PubMed Web of Science ®Google Scholar
• Martin GR.. Pre-clinical pharmacology of zolmitriptan (Zomig™); formerly 311C90), a centrally and peripherally acting5-HT1B/1D agonist for migraine. Cephalalgia 1997;17(Suppl 18):4-14
   PubMedGoogle Scholar
• Moskowitz MA.. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11
   PubMed Web of Science ®Google Scholar
• Smith DA, Cleary EW, Watkins S, Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J Clin Pharmacol 1998;38(8):685-93
   PubMedGoogle Scholar
• Humphrey PPA, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate Cephalalgia 1994;14:401-1025
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997;17:153-8
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Knight YE, Goadsby PJ. Zolmitriptan inhibits c-fos expression in the dorsal horn of the medulla and upper cervical horn evoked by sagittal sinus stimulation in the cat [abstract]. Cephalalgia 1996;16:355
   PubMedGoogle Scholar
• Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70(12):1505-18
   PubMedGoogle Scholar
• Goadsby PJ, Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache 2006;46(1):138-49
   PubMedGoogle Scholar
• Seaber EJ, Peck RW, Smith DA, The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol 1998;46(5):433-9
   PubMedGoogle Scholar
• Yates RA, Tateno M, Nairn K, The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. Eur J Clin Pharmacol 2002;58(4):247-52
   PubMedGoogle Scholar
• Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43(4):376-88
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Antoniazzi AL, The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61(2A):313-20
   PubMedGoogle Scholar
• Zingmark PH, Yates R, Hedlund C, True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray. Eur J Neurol 2003;10(Suppl 1):76
   Google Scholar
• Dodick D, Lipton RB, Martin V, Triptan cardiovascular safety expert panel: consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44:414-25
   PubMed Web of Science ®Google Scholar
• Ottervanger JP, Paalman HJ, Boxma GL, Transmural myocardial infarction with sumatriptan. Lancet 1993;341:861-2
   PubMed Web of Science ®Google Scholar
• Anghileri E, Toso V, Perini F. Acute myocardial infarction after sumatriptan administration for cluster headache. Neurol Sci 2006;26:456-9
   PubMed Web of Science ®Google Scholar
• Weir RA, Oldroyd KG, Walters MR. Myocardial infarction after oral sumatriptan use in a woman with normal coronary arteries. Am J Med 2007;120:7-8
   Web of Science ®Google Scholar
• Ribeiro H, Batista A, Ferreira C, Myocardial infarction after taking zolmitriptan. Portuguese Journal of Cardiology, Rev Port Cardiol 2012;31(2):167-9
   PubMedGoogle Scholar
• Silberstein SD, Holland S, Freitag F, Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337-45
   PubMed Web of Science ®Google Scholar
• Seaber E, On N, Dixon RM, The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 1997;43(6):579-87
   PubMed Web of Science ®Google Scholar
• Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2010;14(4):CD008042
   Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Oral triptans (serotonin 5-HT IB/ID agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Bigal ME, The triptans formulations: how to match patients and products. CNS Drugs 2003;17(6):431-47
   PubMed Web of Science ®Google Scholar
• Charlesworth BR, Dowson AJ, Purdy A, Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17(9):653-67
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008;48:236-47
   PubMed Web of Science ®Google Scholar
• Becker WJ.. Zolmitriptan versus sumatriptan comparison trial. Headache 2001;41:321-3
   PubMed Web of Science ®Google Scholar
• Pascual J, Vega P, Diener HC, Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000;20(5):455-61
   PubMedGoogle Scholar
• Steiner TJ, Diener HC, MacGregor EA, Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23(10):942-52
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Pascual J, Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34-40
   PubMed Web of Science ®Google Scholar
• Peterlin BL, Rapoport A. Clinical pharmacology of the serotonin receptor agonist zolmitriptan. Expert Opin Drug Metab Toxicol 2007;3(6):899-911
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Charlesworth BR, Green J, Zolmitriptan nasal spray exhibits good long term safety and tolerability in migraine: results of the INDEX trial. Headache 2005;45:17-24
   PubMedGoogle Scholar
• Loder E, Silberstein SD, Abu-Shakra S, Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44(2):120-30
   PubMedGoogle Scholar
• Tuchman M, Abu-Shakra S, Silberstein SD, Oral zolmitriptan exhibits high efficacy and low recurrence rates in the acute treatment of true menstrual migraine: results of a randomized controlled trial. Headache 2003;43:512
   Google Scholar
• Tuchman M, Abu-Shakra S, Silberstein SD, Oral zolmitriptan is efficacious as acute therapy for pure menstrual migraine: results of a second large prospective, multicenter, placebo-controlled trial. Neurology 2003;60(Suppl 1):A94
   PubMedGoogle Scholar
• Francis GJ, Becker WJ, Pringsheim TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology 2010;75(5):463-73
   PubMedGoogle Scholar
• Donald WL, Paul W, Andrew DH, Warren WW. Efficacy of Zolmitriptan Nasal Spray in Adolescent Migraine. Pediatrics 2007;120:390
   PubMedGoogle Scholar
• Abu-Arefeh I, Russell G. Prevalence of headache and migraine in school children. BMJ 1994;309:765-9
   PubMed Web of Science ®Google Scholar
• Winner P, Rothner AD, Putnam DG, Demographic and migraine characteristics of adolescents with migraine: GlaxoWellcome clinical trials database. Headache 2003;43:451-7
   PubMedGoogle Scholar
• Schurks M. Genetics of migraine in the age of genome-wide association studies. J Headache Pain 2012;13(1):1-9
   PubMed Web of Science ®Google Scholar
• Ferrari A, Tiraferri I, Neri L, Sternieri E. Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain 2011;12(1):5-12
   PubMed Web of Science ®Google Scholar